CANCER CELLS PRESENT

CANCER CELLS PRESENT was reported 43 times

CANCER CELLS PRESENT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Antiparasitic [EPC] 1 0.0002
1 Pediculicide [EPC] 1 0.0002
2 Programmed Death Ligand-1 Blocker [EPC] 3 0.0001
3 Chloride Channel Activator [EPC] 1 0.0001
4 GLP-2 Analog [EPC] 1 0.0001
5 Radioligand Therapeutic Agent [EPC] 1 0.0001
6 Prostaglandin E1 Analog [EPC] 1 0.0001
7 Janus Kinase Inhibitor [EPC] 8 0.0000
8 Human Immunoglobulin G [EPC] 1 0.0000
9 Bile Acid [EPC] 1 0.0000
10 Progesterone [EPC] 1 0.0000
11 Androgen [EPC] 1 0.0000
12 BCL-2 Inhibitor [EPC] 2 0.0000
13 5-alpha Reductase Inhibitor [EPC] 2 0.0000
14 Tetracycline-class Drug [EPC] 1 0.0000
15 HER2/neu Receptor Antagonist [EPC] 1 0.0000
16 Arteriolar Vasodilator [EPC] 1 0.0000
17 Catecholamine [EPC] 1 0.0000
18 Histamine-1 Receptor Antagonist [EPC] 1 0.0000
19 Purine Antimetabolite [EPC] 1 0.0000
20 Aminosalicylate [EPC] 1 0.0000
21 Expectorant [EPC] 2 0.0000
22 P2Y12 Platelet Inhibitor [EPC] 1 0.0000
23 Histamine-2 Receptor Antagonist [EPC] 1 0.0000
24 Osmotic Laxative [EPC] 2 0.0000
25 Calcium [EPC] 1 0.0000
26 Aldosterone Antagonist [EPC] 1 0.0000
27 Azole Antifungal [EPC] 1 0.0000
28 Microtubule Inhibitor [EPC] 1 0.0000
29 Xanthine Oxidase Inhibitor [EPC] 1 0.0000
30 Kinase Inhibitor [EPC] 3 0.0000
31 Estrogen [EPC] 1 0.0000
32 Thiazide Diuretic [EPC] 1 0.0000
33 Vitamin C [EPC] 2 0.0000
34 Thalidomide Analog [EPC] 2 0.0000
35 Platinum-based Drug [EPC] 1 0.0000
36 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
37 Angiotensin 2 Receptor Blocker [EPC] 1 0.0000
38 Dihydropyridine Calcium Channel Blocker [EPC] 1 0.0000
39 Benzodiazepine [EPC] 2 0.0000
40 GLP-1 Receptor Agonist [EPC] 1 0.0000
41 Platelet Aggregation Inhibitor [EPC] 1 0.0000
42 Proton Pump Inhibitor [EPC] 1 0.0000
43 Nonsteroidal Anti-inflammatory Drug [EPC] 2 0.0000
44 Tumor Necrosis Factor Blocker [EPC] 1 0.0000